| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33d92d743ac65427288165394c2e5d33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_954f9be6595d50ddf4dc40b0ea7a5718
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96eddd31165955882708d73c89118259 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-28 |
| filingDate |
2012-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48bad47261341373faa09a30e2b8320a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92f95cab2443f7c19d78f385808421a7 |
| publicationDate |
2013-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013338372-A1 |
| titleOfInvention |
Substituted Imidazoline Compounds |
| abstract |
The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008114015-A1 |
| priorityDate |
2007-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |